Post-Interleukin 6
siltuximab, tocilizumab, SGP130Fc
32353761 2020. Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review
32247642 ä. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report
32243501 2020. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
32343968 ä. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report
32337664 ä. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
32359035 2020. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19
32378647 2020. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
32234467 ä. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
32305588 ä. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies
32291137 ä. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
32300051 2020. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
C7154570 2020. Anti-IL6R role in treatment of COVID-19-related ARDS
32290839 2020. Why tocilizumab could be an effective treatment for severe COVID-19?
32372149 ä. SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?
32367812 2020. Fyrsta meethfereth meeth tocilizumab vieth COVID-19 herlendis - sjukratilfelli
32327746 ä. Translating IL-6 biology into effective treatments
32325121 ä. Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19
32380318 ä. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection
32359210 2020. Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report
32324331 2020. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine
32376396 ä. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
32376398 ä. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
32299796 2020. Antirheumatic agents in covid-19: is IL-6 the right target?
32369612 2020. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma
32278585 2020. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab
32352361 2020. Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists
32253759 2020. Tocilizumab treatment in COVID-19: A single center experience
32171193 2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies
32209313 2020. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws
32369191 2020. Tocilizumab for the treatment of severe coronavirus disease 2019
32297987 2020. Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection
32358817 2020. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome
32282956 2020. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab
C7187784 ä. Case Study: A Patient with Asthma, Covid-19 Pneumonia and Cytokine Release Syndrome Treated with Corticosteroids and Tocilizumab
32350134 2020. Effective treatment of severe COVID-19 patients with tocilizumab
32365207 ä. Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report
32376396 2020. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
32380318 2020. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection
32402416 ä. Perforacion intestinal en paciente COVID-19 en tratamiento con tocilizumab y corticoides ...
| 32321563 2020. IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome |
32389721 ä. Tocilizumab in COVID-19: Beware the risk of intestinal perforation
C7154570 2020. Anti-IL6R role in treatment of COVID-19-related ARDS
32393681 2020. Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.
32387320 ä. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
32397399 2020. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).
32500936 2020. Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.
32391669 2020. [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].
32436994 2020. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
32505467 2020. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
32492210 2020. Tocilizumab Administration in Patients with SARS-CoV-2 Infection: Subcutaneous Injection versus Intravenous Infusion.
32499314 2020. Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.
32503815 2020. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
32485858 2020. Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells.
32500858 2020. Serum concentrations of interleukin-6 (IL-6) in the general adult population: possible implications for anti-IL-6 therapy in SARS-Cov-2 infection and IL-6-related diseases.
32488861 2020. Applied Clinical Pharmacology in a Crisis - Interleukin-6 Axis Blockade and COVID-19.
32480422 2020. Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia.
32457999 2020. Tocilizumab not associated with increased infection risk after CAR T - Implications for COVID-19?
32406282 2020. Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces.
32452345 2020. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart.
32495916 2020. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
32470146 2020. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis.
32462717 2020. COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
32456769 2020. Early tocilizumab treatment could improve survival among COVID-19 patients.
| 32409439 2020. Practical aspects of targeting IL-6 in COVID-19 disease. |
32484930 2020. Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients.
32484915 2020. Feasibility of Tocilizumab in ICU patients with COVID-19.
32421092 2020. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.
32476261 2020. Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2.
